Analyse the Efficacy and Safety of Intravitreal Injection of Biosimilar Ranibizumab on Central Macular Thickness and Visual Outcome in Patients of Macular Edema

The biosimilar ranibizumab like its biologic reference drug (Lucentis; Genentech) is a recombinant humanized IgG1 monoclonal antibody designed for intraocular use. Recombinant humanized IgG1 kappa isotype monoclonal antibody fragment, inhibits the biologic activity of human VEGF-A. In this paper, efficacy of single intravitreal injection of biosimilar ranibizumab on central macular thickness and visual outcome in patients of macular oedema with different retinal etiology is presented. Effect of biosimilar intravitreal ranibizumab for DME, pseudo phakic cystoid macular edema and macular edema secondary to RVO was observed over period of 3 months with improvements in visual acuity and CFT without detectable ocular and systemic toxicity.